Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dermal filler approved

This article was originally published in The Gray Sheet

Executive Summary

Sanofi-Aventis' injectable poly-L-lactic acid Sculptra Aesthetic receives supplemental PMA approval for correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles, the company announced July 28. The approval was supported by a multi-center study that randomized 233 patients to either Sculptra or an approved human-derived collagen, the company said in a July 29 release. Results showed that Sculptra effects were maintained for up to 25 months after the last treatment, versus three months with the human-derived collagen. Sculptra was originally approved in 2004 for facial lipoatrophy

You may also be interested in...



News In Brief

Valeant gains Sculptra for wrinkles

Waters Muddied As Bharat Readies COVID-19 Vaccine For '21 Launch

As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.

PMDA Eyes More Japan-First Approvals In Access Push

Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.

Topics

UsernamePublicRestriction

Register

OM004967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel